Charmacy Pharmaceutical Co., Ltd.
Charmacy Pharmaceutical Co., Ltd. Fundamental Analysis
Charmacy Pharmaceutical Co., Ltd. (2289.HK) shows weak financial fundamentals with a PE ratio of 11.41, profit margin of 1.14%, and ROE of 7.98%. The company generates $4.2B in annual revenue with weak year-over-year growth of 0.72%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 21.0/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze 2289.HK's fundamental strength across five key dimensions:
Efficiency Score
Weak2289.HK struggles to generate sufficient returns from assets.
Valuation Score
Excellent2289.HK trades at attractive valuation levels.
Growth Score
Moderate2289.HK shows steady but slowing expansion.
Financial Health Score
Moderate2289.HK shows balanced financial health with some risks.
Profitability Score
Weak2289.HK struggles to sustain strong margins.
Key Financial Metrics
Is 2289.HK Expensive or Cheap?
P/E Ratio
2289.HK trades at 11.41 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, 2289.HK's PEG of -1.30 indicates potential undervaluation.
Price to Book
The market values Charmacy Pharmaceutical Co., Ltd. at 0.93 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 0.06 times EBITDA. This is generally considered low.
How Well Does 2289.HK Make Money?
Net Profit Margin
For every $100 in sales, Charmacy Pharmaceutical Co., Ltd. keeps $1.14 as profit after all expenses.
Operating Margin
Core operations generate 1.58 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $7.98 in profit for every $100 of shareholder equity.
ROA
Charmacy Pharmaceutical Co., Ltd. generates $1.38 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Charmacy Pharmaceutical Co., Ltd. generates limited operating cash flow of $280.74M, signaling weaker underlying cash strength.
Free Cash Flow
Charmacy Pharmaceutical Co., Ltd. produces free cash flow of $274.89M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $2.55 in free cash annually.
FCF Yield
2289.HK converts 49.91% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
11.41
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-1.30
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.93
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.13
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
1.78
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.09
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.08
vs 25 benchmark
ROA
Return on assets percentage
0.01
vs 25 benchmark
ROCE
Return on capital employed
0.10
vs 25 benchmark
How 2289.HK Stacks Against Its Sector Peers
| Metric | 2289.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 11.41 | 28.45 | Better (Cheaper) |
| ROE | 7.98% | 763.00% | Weak |
| Net Margin | 1.14% | -45266.00% (disorted) | Weak |
| Debt/Equity | 1.78 | 0.34 | Weak (High Leverage) |
| Current Ratio | 1.09 | 2795.60 | Neutral |
| ROA | 1.38% | -16586.00% (disorted) | Weak |
2289.HK outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Charmacy Pharmaceutical Co., Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
27.00%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
32.72%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
2538.75%
Industry Style: Defensive, Growth, Innovation
High Growth